1. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry;Kerem;Eur Respir J,2014
2. CFTR, bicarbonate, and the pathophysiology of cystic fibrosis;Borowitz;Pediatr Pulmonol,2015
3. Vertex Pharmaceuticals Incorporated. Highlights or prescribing information for KALYDECO® 2019, https://pi.vrtx.com/files/uspi_ivacaftor.pdf; 2019 [accessed January 16, 2020].
4. Vertex Pharmaceuticals Incorporated. Highlights of prescribing information for ORKAMBI®. 2018, https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf; 2019 [accessed January 16, 2020].
5. Lumacaftor–Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR;Wainwright;N Engl J Med,2015